Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | HTR1A | P08908 | 1/20 | 0.43 |
| ▸ | HTR1D | P28221 | 1/20 | 0.43 |
| ▸ | HTR1B | P28222 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.40 |
| ▸ | USP2 | O75604 | 1/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.39 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.39 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.39 |
| ▸ | POLB | P06746 | 2/20 | 0.39 |
| ▸ | LMNA | P02545 | 4/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 4/20 | 0.38 |
| ▸ | MEN1 | O00255 | 3/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16112967 | 0.89 | KRAS (0.49) | GAAHTR1AHTR1DHTR1BMAPK1 | |
| SCHEMBL16112968 | 0.89 | KRAS (0.49) | GAAHTR1AHTR1DHTR1BMAPK1 | |
| SCHEMBL25936148 | 0.81 | KRAS (0.55) | GAAHTR1AHTR1DHTR1BALDH1A1 | |
| SCHEMBL16144079 | 0.81 | KRAS (0.48) | GAAMAPK1USP2ALDH1A1SMN1; SMN2 | |
| SCHEMBL16144129 | 0.81 | KRAS (0.46) | GAAMAPK1USP2ALDH1A1SMN1; SMN2 | |
| SCHEMBL19997011 | 0.79 | GAA (0.43) | GAAALDH1A1SMN1; SMN2POLBLMNA | |
| SCHEMBL22550951 | 0.76 | KRAS (0.66) | GAAALDH1A1SMN1; SMN2POLBLMNA | |
| SCHEMBL21401576 | 0.74 | GAA (0.44) | GAAALDH1A1SMN1; SMN2L3MBTL1POLB | |
| SCHEMBL15337756 | 0.73 | KRAS (0.60) | GAAPOLBKDM4ERAB9AMAPT | |
| SCHEMBL25930494 | 0.73 | GAA (0.44) | GAAALDH1A1SMN1; SMN2POLBLMNA |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10723753-B2 | Ras inhibitors and uses thereof | DANA-FARBER CANCER INSTITUTE, INC. (US) | 2020-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10723753-B2 | Ras inhibitors and uses thereof | KRAS, NRAS, RASGRP1 | GAA 2130/4885HTR1A 4483/4885HTR1D 4654/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.